Mural Oncology plc (MURA)
Delisted
9 Dec 2025
NASDAQ (NMS) NASDAQ (NMS) Primary $
2. 04
0
0%
$
35.21M Market Cap
- P/E Ratio
- Div Yield
127,775 Volume
0 Eps
$ 2.04
Previous Close Investors:
Day Range
2.04 2.04
Year Range
0.95 4.74
Want to track MURA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
Zacks | 1 year ago
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian cancer.
Benzinga | 1 year ago
